S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
NASDAQ:HSDT

Helius Medical Technologies Stock Forecast, Price & News

$4.16
-0.24 (-5.45%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.11
▼
$4.40
50-Day Range
$3.70
▼
$7.61
52-Week Range
$3.70
▼
$20.98
Volume
9,993 shs
Average Volume
17,527 shs
Market Capitalization
$9.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.93
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive HSDT News and Ratings via Email

Sign-up to receive the latest news and ratings for Helius Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.


Helius Medical Technologies logo

About Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Headlines

ROOT, MTR and HSDT among mid-day movers
January 23, 2022 |  seekingalpha.com
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Update
January 18, 2022 |  americanbankingnews.com
Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke
December 17, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®
December 14, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc.’s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Conference on December 9
December 6, 2021 |  finance.yahoo.com
CEO Of Helius Medical Tech Makes $300K Buy
November 15, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. to Participate in 1x1 Meetings at 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021
November 15, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. Announces Closing of $11.1 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option
November 12, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results
November 10, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Tops Revenue Estimates
November 10, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering of Common Stock
November 10, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock
November 9, 2021 |  finance.yahoo.com
Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSDT
Previous Symbol
CUSIP
N/A
CIK
1610853
Web
heliusmedical.com
Phone
(215) 944-6100
Fax
N/A
Employees
19
Year Founded
N/A

Sales & Book Value

Annual Sales
$660 thousand
Price / Sales
15.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
1.61

Profitability

EPS (Most Recent Fiscal Year)
($8.01)
Net Income
$-14.13 million
Net Margins
-3,640.44%
Pretax Margin
-3,640.66%
Return on Equity
-227.11%
Return on Assets
-166.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.36
Quick Ratio
2.16

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
2,394,000
Free Float
1,977,000
Market Cap
$9.96 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/28/2022
Next Earnings (Estimated)
3/09/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.99 out of 5 stars

Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Helius Medical Technologies (NASDAQ:HSDT) Frequently Asked Questions

Is Helius Medical Technologies a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Helius Medical Technologies stock.
View analyst ratings for Helius Medical Technologies or view top-rated stocks.

Are investors shorting Helius Medical Technologies?

Helius Medical Technologies saw a increase in short interest in December. As of December 31st, there was short interest totaling 33,700 shares, an increase of 37.0% from the December 15th total of 24,600 shares. Based on an average daily volume of 25,500 shares, the days-to-cover ratio is currently 1.3 days.
View Helius Medical Technologies' Short Interest.

When is Helius Medical Technologies' next earnings date?

Helius Medical Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Helius Medical Technologies.

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($2.01) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.75) by $0.26. The business earned $0.11 million during the quarter, compared to analyst estimates of $0.08 million. Helius Medical Technologies had a negative trailing twelve-month return on equity of 227.11% and a negative net margin of 3,640.44%. During the same quarter in the prior year, the firm earned ($2.80) EPS.
View Helius Medical Technologies' earnings history.

When did Helius Medical Technologies' stock split? How did Helius Medical Technologies' stock split work?

Helius Medical Technologies's stock reverse split on Thursday, December 31st 2020. The 1-35 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 4th 2021. An investor that had 100 shares of Helius Medical Technologies stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for HSDT?

2 Wall Street analysts have issued 12-month price objectives for Helius Medical Technologies' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Helius Medical Technologies' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 380.8% from the stock's current price.
View analysts' price targets for Helius Medical Technologies or view top-rated stocks among Wall Street analysts.

Who are Helius Medical Technologies' key executives?

Helius Medical Technologies' management team includes the following people:
  • Dane Carl Andreeff, President, Chief Executive Officer & Director
  • Jeffrey S. Mathiesen, Chief Financial Officer, Secretary & Treasurer
  • Antonella Favit-van Pelt, Chief Medical Officer
  • Frederick Fantazzia, VP-Sales & Marketing North America Region
  • Jack Powell, Vice President-Investor Relations

What is Helius Medical Technologies' stock symbol?

Helius Medical Technologies trades on the NASDAQ under the ticker symbol "HSDT."

How do I buy shares of Helius Medical Technologies?

Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Helius Medical Technologies' stock price today?

One share of HSDT stock can currently be purchased for approximately $4.16.

How much money does Helius Medical Technologies make?

Helius Medical Technologies has a market capitalization of $9.96 million and generates $660 thousand in revenue each year. The company earns $-14.13 million in net income (profit) each year or ($8.01) on an earnings per share basis.

How many employees does Helius Medical Technologies have?

Helius Medical Technologies employs 19 workers across the globe.

What is Helius Medical Technologies' official website?

The official website for Helius Medical Technologies is heliusmedical.com.

Where are Helius Medical Technologies' headquarters?

Helius Medical Technologies is headquartered at 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940.

How can I contact Helius Medical Technologies?

Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at (215) 944-6100 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.